ABBV stock forecast, quote, news & analysis

Key Takeaways

• AbbVie shares are trading near $285, up roughly 8% over the trailing 30 days and approximately 26% year-to-date, reflecting broad strength in large-cap healthcare.
• Second-quarter 2026 revenue rose 10.2% year over year to nearly $17 billion, while adjusted earnings per share of $3.65 beat the midpoint of company guidance.
• Skyrizi and Rinvoq remain the core growth engines, growing 24% and nearly 24% operationally, respectively, and more than offsetting Humira's biosimilar-driven decline.
• The $10.9 billion acquisition of Apogee Therapeutics, completed in early September 2026, deepens the immunology pipeline with long-acting candidates aimed at the 2030s.
• Management raised full-year 2026 revenue guidance to about $67.6 billion and reaffirmed adjusted EPS guidance of $13.87 to $14.07.
• For more detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages.
• Explore Trending AI Robots to see how automated trading systems approach this and other tickers.

Current Market Snapshot

AbbVie has traded with a generally upward bias through the late-summer and early-autumn period. After consolidating in the mid-$240s in early August, shares advanced through the $260s and $270s in September and October, reaching a recent close near $285.64. The stock's roughly 8% advance over the trailing 30 days places it in a steady, moderate-appreciation pattern rather than a sharp breakout, consistent with a defensive pharmaceutical holding supported by dependable cash flows and a reliable dividend.

Broader sentiment has favored large-cap biopharma names with visible growth visibility, and AbbVie's diversified portfolio across immunology, neuroscience, and oncology has kept investor focus on execution rather than a single product's patent cycle. The forward dividend yield remains well above the broader market average, reinforcing the stock's appeal to income-oriented investors.

AbbVie (ABBV) Business Overview and Competitive Position

AbbVie is a global biopharmaceutical company headquartered in North Chicago, Illinois, focused on immunology, oncology, neuroscience, and aesthetics. Its portfolio includes the blockbuster immunology treatments Skyrizi (risankizumab) and Rinvoq (upadacitinib), the legacy inflammatory drug Humira (adalimumab), neuroscience products such as Vraylar and Botox Therapeutic, migraine medicines Ubrelvy and Qulipta, and oncology therapies including Venclexta and Imbruvica.

The company's defining strategic challenge has been navigating the loss of exclusivity on Humira, once the world's top-selling drug. AbbVie has responded by shifting growth to Skyrizi and Rinvoq, which continue to post strong double-digit gains, while broadening into neuroscience and oncology. This diversification, combined with a pipeline of roughly 90 compounds, devices, or indications, positions AbbVie as a core holding in large-cap healthcare and a widely followed Dividend King with decades of consecutive payout increases.

Recent Developments Driving ABBV

Several verified developments have shaped the stock's recent trajectory. In late July, AbbVie reported second-quarter results that exceeded its own expectations, with net revenue of nearly $17 billion rising 10.2% year over year. Skyrizi generated $5.5 billion in quarterly sales, up 24% operationally, while Rinvoq surpassed $2.5 billion, up 23.7%. Neuroscience revenue also climbed roughly 20%, led by Vraylar, Botox Therapeutic, and the migraine franchise.

Management raised full-year revenue guidance by $300 million to approximately $67.6 billion, though the company trimmed adjusted EPS guidance to $13.87–$14.07 to account for dilution tied to its acquisition of APGE (Apogee Therapeutics). That approximately $10.9 billion all-cash deal closed in early September, adding zumilokibart, a late-stage IL-13 antibody for atopic dermatitis, and an early asthma program. Regulatory momentum has also supported sentiment, including European approvals for Rinvoq in vitiligo and alopecia areata and an expected U.S. decision on Skyrizi's subcutaneous induction in Crohn's disease later in 2026.

Trending AI Robots

Tickeron operates a broad ecosystem of AI-driven trading bots that monitor thousands of tickers, but only the strongest and most relevant performers are surfaced in its curated Trending AI Robots section. These bots vary widely in strategy, holding timeframe, and performance metrics, allowing traders and investors to compare approaches ranging from short-term momentum to longer-horizon pattern recognition. By focusing on a rotating selection of top-performing bots, the page offers a practical starting point for those interested in systematic, data-driven market analysis. Readers can browse the section to see which automated strategies are currently drawing attention across the market.

2026 Outlook and What Investors Should Watch

Looking ahead, investors will monitor several catalysts. The U.S. regulatory decision on Skyrizi's subcutaneous induction for Crohn's disease is expected before year-end, with broader payer access anticipated in early 2027. Additional Rinvoq label expansions, including potential U.S. decisions in vitiligo and alopecia areata, could extend the immunology franchise further. The integration of the Apogee pipeline and the progression of combination immunology candidates such as ABBV-466 represent longer-horizon drivers.

Key risks include continued Humira erosion from biosimilar competition, pricing pressure from measures such as U.S. drug-price negotiation, and execution risk across clinical programs and the Apogee integration. Third-quarter results, guided to about $17.2 billion in revenue with adjusted EPS of $3.84 to $3.88, will offer the next checkpoint on momentum into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations